These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26156324)

  • 1. The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
    Ak G; Metintas S; Akarsu M; Metintas M
    BMC Cancer; 2015 Jul; 15():510. PubMed ID: 26156324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
    Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE; Fahmy ES
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Pinto C; Zucali PA; Pagano M; Grosso F; Pasello G; Garassino MC; Tiseo M; Soto Parra H; Grossi F; Cappuzzo F; de Marinis F; Pedrazzoli P; Bonomi M; Gianoncelli L; Perrino M; Santoro A; Zanelli F; Bonelli C; Maconi A; Frega S; Gervasi E; Boni L; Ceresoli GL
    Lancet Oncol; 2021 Oct; 22(10):1438-1447. PubMed ID: 34499874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
    Pasello G; Nicotra S; Marulli G; Rea F; Bonanno L; Carli P; Magro C; Jirillo A; Favaretto A
    Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
    de Lima VA; Sørensen JB
    Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
    Lee CW; Murray N; Anderson H; Rao SC; Bishop W
    Lung Cancer; 2009 Jun; 64(3):308-13. PubMed ID: 19004520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
    Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study.
    Aerts JG; Belderbos R; Baas P; Scherpereel A; Bezemer K; Enninga I; Meijer R; Willemsen M; Berardi R; Fennell D; Kerstens R; Cornelissen R; van Meerbeeck JP;
    Lancet Oncol; 2024 Jul; 25(7):865-878. PubMed ID: 38848742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience.
    Sezgin Y; Karhan O; Ileri S; Ebinc S; Tunc S; Urakci Z
    J Coll Physicians Surg Pak; 2024 Aug; 34(8):904-909. PubMed ID: 39113507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
    Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
    Jänne PA; Simon GR; Langer CJ; Taub RN; Dowlati A; Fidias P; Monberg M; Obasaju C; Kindler H
    J Clin Oncol; 2008 Mar; 26(9):1465-71. PubMed ID: 18349397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA
    Cancer Treat Rev; 2015 Dec; 41(10):853-8. PubMed ID: 26526504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
    Favaretto AG; Aversa SM; Paccagnella A; Manzini Vde P; Palmisano V; Oniga F; Stefani M; Rea F; Bortolotti L; Loreggian L; Monfardini S
    Cancer; 2003 Jun; 97(11):2791-7. PubMed ID: 12767092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    Simon GR; Verschraegen CF; Jänne PA; Langer CJ; Dowlati A; Gadgeel SM; Kelly K; Kalemkerian GP; Traynor AM; Peng G; Gill J; Obasaju CK; Kindler HL
    J Clin Oncol; 2008 Jul; 26(21):3567-72. PubMed ID: 18640937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
    Mutlu H; Gündüz S; Karaca H; Büyükçelik A; Cihan YB; Erden A; Akca Z; Coşkun HS
    Med Oncol; 2014 Aug; 31(8):74. PubMed ID: 24958517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.